Mihir Raval
Hematology & Oncology · Albany, NYNPI 1962639427
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $576,358 of the $766,610 with a category attached, or 75.2%. It is spread thinly across 31 manufacturers, the largest accounting for just 23.5%. Among hematology & oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 594 payments — averaging $1290.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$180K
- Takeda Pharmaceuticals U.S.A., Inc.$126K
- GSK$83K
- Sanofi$70K
- E.r. Squibb & Sons, L.L.C.$55K
- Incyte Corporation$52K
- plus $200K from 25 others
Across 368 payments — averaging $2347.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$301K
- Seagen Inc.$282K
- AbbVie$120K
- Amgen$67K
- Pfizer$22K
- Merck$19K
- plus $53K from 6 others
What the payments were for
- Consulting fees$125,67516%
- Speaking & faculty fees$576,35875%
- Travel & lodging$48,3376%
- Food & beverage$15,9552%
- Education$2850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 141 | $180,087 |
| Takeda Pharmaceuticals U.S.A., Inc. | 85 | $126,158 |
| GSK | 46 | $82,997 |
| Sanofi | 42 | $69,800 |
| E.r. Squibb & Sons, L.L.C. | 36 | $55,492 |
| Incyte Corporation | 63 | $52,463 |
| AbbVie | 26 | $33,697 |
| Epizyme, Inc. | 29 | $33,382 |
| Agios Pharmaceuticals, Inc. | 19 | $21,498 |
| Adaptive Biotechnologies Corporation | 14 | $20,549 |
| Beigene USA, Inc. | 15 | $19,727 |
| ADC Therapeutics America, Inc. | 12 | $18,792 |
| Ipsen Biopharmaceuticals, Inc | 5 | $11,938 |
| Astellas Pharma US Inc | 8 | $7,835 |
| Bristol Myers Squibb | 12 | $5,641 |
| Syndax Pharmaceuticals, Inc. | 6 | $4,184 |
| Johnson & Johnson | 5 | $3,560 |
| Geron Corporation | 2 | $3,448 |
| CTI Biopharma Corp. | 3 | $3,423 |
| Lilly USA, LLC | 1 | $2,813 |
| Beone Medicines USA, Inc. | 2 | $2,557 |
| Morphosys, US Inc. | 2 | $2,225 |
| Pharmaessentia USA Corporation | 1 | $1,845 |
| Jazz Pharmaceuticals Inc. | 1 | $1,500 |
| Genmab U.S., Inc. | 1 | $600 |
| Seagen Inc. | 1 | $124 |
| Pfizer | 11 | $111 |
| Gilead | 2 | $75 |
| Novartis | 1 | $60 |
| Stemline Therapeutics Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$766,610 in reported general payments places this provider in the 95th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 101 | $1,389,158 |
| RevlimidLenalidomide | 55 | $931,043 |
| JakafiRuxolitinib Phosphate | 69 | $881,666 |
| CalquenceAcalabrutinib Maleate | 59 | $803,715 |
| BrukinsaZanubrutinib | 46 | $567,453 |
| OjjaaraMomelotinib Dihydrochloride | 20 | $542,788 |
| VenclextaVenetoclax | 45 | $438,008 |
| NinlaroIxazomib Citrate | 34 | $424,081 |
| PomalystPomalidomide | 17 | $298,493 |
| IclusigPonatinib Hcl | 11 | $235,008 |
| ErleadaApalutamide | 12 | $182,137 |
| ImbruvicaIbrutinib | 11 | $176,148 |
| EliquisApixaban | 176 | $163,711 |
| PromactaEltrombopag Olamine | 12 | $154,394 |
| ZarxioFilgrastim-Sndz | 37 | $70,007 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $5,641 | $931,04355 claims |
| Incyte CorporationJakafi | $52,463 | $881,66669 claims |
| AstraZenecaCalquence | $180,087 | $803,71559 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro, Iclusig | $126,158 | $659,09045 claims |
| Beigene USA, Inc.Brukinsa | $19,727 | $567,45346 claims |
| GSKOjjaara | $82,997 | $542,78820 claims |
| AbbVieVenclexta | $33,697 | $438,00845 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $55,492 | $298,49317 claims |
| Johnson & JohnsonErleada, Xarelto | $3,560 | $204,73341 claims |
| PfizerEliquis | $111 | $163,711176 claims |
| NovartisPromacta | $60 | $154,39412 claims |
| Lilly USA, LLCOlanzapine | $2,813 | $30311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in Albany
- Rahul RavillaAlbany$351K
- Ira ZackonAlbany$127K
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Joshua SabariNew York$761K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.